Who is sponsoring NCT04386213?

NCT04386213 is sponsored by Shanghai MicroPort Medical (Group) Co., Ltd..

What drugs are being tested in NCT04386213?

Interventions in NCT04386213: coronary artery in-stent restenosis.

What condition does NCT04386213 study?

NCT04386213 studies Coronary Artery In-stent Restenosis.

Is NCT04386213 still recruiting?

NCT04386213 is currently status unknown. Last updated 13 May 2020.

Last reviewed 2020-05-13 · How we verify

NCT04386213

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial for MicroPort's DCB

Status unknown NA Last updated 13 May 2020

What this trial tests

NA trial testing coronary artery in-stent restenosis in Coronary Artery In-stent Restenosis in 216 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
1 December 2023

31 July 2025

Quick facts

Lead sponsor	Shanghai MicroPort Medical (Group) Co., Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	216
Start date	1 September 2020
Primary completion	1 December 2023
Estimated completion	31 July 2025

Drugs / interventions tested

coronary artery in-stent restenosis

Conditions studied

Coronary Artery In-stent Restenosis — all drugs for Coronary Artery In-stent Restenosis →

Sponsor

Shanghai MicroPort Medical (Group) Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Coronary Artery In-stent Restenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter, randomized, controlled clinical research and aims to evaluate the safety and efficacy of the paclitaxel drug-coated coronary artery balloon catheter in patients with coronary artery in-stent restenosis compared to seQuent® please paclitaxel drug-coated coronary artery balloon catheter.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai MicroPort Medical (Group) Co., Ltd. trials

Trials by the same sponsor.

NCT04951050 — TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment · NA · active not recruiting
NCT04479722 — Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke · NA · active not recruiting
NCT04918615 — Compare Sirolimus Coated Balloon Catheter With Paclitaxel Coated Balloon Catheter in De Novo Coronary Bifurcated Lesions · NA · unknown
NCT04562532 — Firehawk Rapamycin Target Eluting Coronary Stent North American Trial · NA · active not recruiting
NCT04538001 — Safety and Efficacy of Rotator Cuff Function Restoration Balloon in Irreparable Rotator Cuff Tear · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04386213 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai MicroPort Medical (Group) Co., Ltd.
Last refreshed: 13 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04386213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing